Pezzella Francesco
Nuffield Division of Clinical Laboratory Science, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK.
Cancer Drug Resist. 2019 Sep 19;2(3):595-607. doi: 10.20517/cdr.2019.39. eCollection 2019.
Hailed as the cancer treatment to end all the resistance to treatment, anti-angiogenic therapy turned out to be not quite what was promised. The hope that this therapeutic approach would not have suffered by the phenomenon of resistance was based on the fact that was targeting normal vessels rather than tumour cells prone to mutation and subject to drug induced selection. However, reality turned out to be more complex and since 1997, several mechanisms of resistance have been described to the point that the study of resistance to these drugs is now a very large field. Far from being exhaustive, this paper presents the main mechanisms discovered trough some examples.
抗血管生成疗法被誉为终结所有治疗抵抗的癌症治疗方法，但事实证明并非如此。人们希望这种治疗方法不会受到耐药现象的影响，这是基于它针对的是正常血管而非易于突变且会受到药物诱导选择的肿瘤细胞。然而，现实情况更为复杂，自1997年以来，已经描述了几种耐药机制，以至于目前对这些药物耐药性的研究已成为一个非常庞大的领域。本文远非详尽无遗，而是通过一些例子介绍了发现的主要机制。
